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ABSTRACT
The immunologic hallmark of atopic allergy and
asthma is an increased production of IgE and T helper
(h) type 2 cell cytokines (interleukin (IL)-4, IL-5, IL-9
and IL-13) by Th cells reacting to common environ-
mental allergens. All of us inhale allergens and
healthy non-atopics produce allergen-specific IgG1,
IgG4 and the Th1 cytokine interferon-α, as well as 
IL-12 from macrophages. We now have many modal-
ities of immunomodulation to decrease the effect of 
IL-4 or IL-5 or production and level of IgE or agents 
to shift the immune response from a Th2 to a Th1
response, thereby decreasing the allergic inflamma-
tory response in the airways. In the present review we
focus on conventional immunotherapy, mycobacterial
vaccines, DNA vaccines using cytosine guanosine,
inhibitors of IL-4 and IL-5 and anti-IgE: Omalizumab.
Key words: bacillus Calmette–Guérin vaccine,
bronchial asthma, cytosine guanosine oligonu-
cleotide, eosinophils, IgE/anti-IgE, immunotherapy,
Th1/Th2 cytokines.
CONVENTIONAL IMMUNOTHERAPY
The immunologic hallmark of atopic allergy and asthma
is an increased production of IgE and T helper (Th) 2 cell
cytokines, such as interleukin (IL)-4, IL-5, IL-9 and IL-13,
by Th cells reacting to common environmental allergens.
All of us inhale allergens and healthy non-atopics
produce allergen-specific IgG1, IgG4 and the Th1
cytokine interferon (IFN)-γ as well as IL-12 from macro-
phages. Conventional immunotherapy is characterized
by an increase in IgG1, IgG4, IFN-γ and IL-12. It is 
very effective and lasts for at least 3 years after dis-
continuation.1 Immunotherapy induces a shift from Th2
cytokine production to Th1, inhibition of the early and
late-phase allergy skin test reactions. Unfortunately,
patients receiving conventional immunotherapy are at
risk for anaphylaxis.
Allergen immunotherapy is the only therapeutic
modality that can affect the natural course of allergic 
diseases and may prevent the development of asthma in
patients with allergic rhinitis. Allergen immunotherapy 
is indicated for patients with demonstrated specific IgE
antibodies against clinically relevant allergens. Allergen
vaccine immunotherapy induces tolerance to allergens.
Allergen immunotherapy, as well as guidelines, updates
and recommendations of the World Health Organizations
was recently summarized by Theodoropoulus and Lockey.2
Allergen-induced late responses in the skin and nose
following immunotherapy are associated with a decrease
in CD4+ cell recruitment and a reduction in local
eosinophilia. These changes are associated with an
increase in CD4+ cells expressing IFN-γ following aller-
gen provocation. This late increase in IFN-γ-producing
cells correlates closely with the clinical response to aller-
gen immunotherapy. Upregulated Th1 responses are
protective against allergen-induced responses.3 The 
production of IL-12 amplifies the Th1 response. There is
a reciprocal association between IL-12+ cells and IL-4+
cells.4
Immunotherapy also induces tolerance through multi-
ple effects on immune cells, which includes an increase 
in the generation of allergen-specific CD8+ cells and
enhancement of the Th1 response by increasing the
Allergology International (2002) 51: 63–73
Review Article
Immunomodulation in the treatment and/or prevention
of bronchial asthma
Robert G Townley, Russell J Hopp, Devendra K Agrawal, Thomas B Casale and 
Michael T Hopfenspirger
Creighton University Center for Allergy, Asthma and Immunology, Omaha, Nebraska, USA
Correspondence: Dr Robert G Townley, 601 N 30th Street,
Suite 1630, Omaha, NE 68131, USA. 
Email: rtownley@creighton.edu
Received 18 December 2001.
64 RG TOWNLEY
number of IFN-γ-producing cells. Immunotherapy also
increases the production of IFN-γ-responding cells, such
as mononuclear phagocytes, B cells and NK cells.
Allergen immunotherapy is highly effective in selected
patients with IgE-mediated disease. It also provides
insight into the basis of allergic disease and assists in
further development of therapeutic strategies. It reduces
immediate allergen-induced symptoms and reduces the
concentration of mediators in the target organ of the
allergic disease. It also decreases the nasal epithelial
mast cells.5 Furthermore, allergen immunotherapy has a
striking ability to inhibit the late-phase response and
results in the decline of IgE levels over several years. This
is associated with an increase in allergen-specific IgG
and results in a modified T lymphocyte response to
subsequent natural allergen exposure. This results in
the shift of the balance from Th2 to Th1 responses.
Allergen immunotherapy results in suppression of the
late nasal response and an increase in cells expressing
mRNA for IFN-γ. It results in increased levels of IL-12,
which is a potent inducer of Th1-type T cell differentia-
tion. The inhibition of the late cutaneous response is
associated with an increase in IL-12 mRNA-positive cells.
An attractive hypothesis of the mechanism of immuno-
therapy is that it results in a shift in favor of a Th1-type
response that may occur either as a consequence of
selected downregulation, or anergy, of the Th2 response
or as immune deviation under the influence of IL-12.
Frequently, asthma and allergic rhinitis coexist and the
potential for allergic rhinitis to precipitate or exacerbate
asthma constitutes an additional reason for immuno-
therapy in asthma.1,3,4
Pollen immunotherapy was also associated with
improvement in symptoms of asthma, as well as allergic
rhinitis. In placebo-treated control subjects, there was a
very significant increase in airway reactivity to metha-
choline during the pollen season. In contrast, the airway
reactivity of asthmatic subjects receiving immunotherapy
did not increase during the pollen season.6,7
A meta-analysis of 62 randomized, controlled trials on
allergen immunotherapy for asthma shows significant
and homogenous improvement in asthma symptoms 
with pollen, animal dander and other vaccines.8 Para-
meters that show the most significant and consistent
improvement after immunotherapy are allergen-specific
bronchial hyperresponsiveness and medication require-
ments. Improvements in allergen-specific bronchial hyper-
responsiveness following immunotherapy is reported in a
meta-analysis of randomized, controlled trials.8
Normal individuals who are not atopic but are exposed
to the same concentrations of allergens as patients with
allergy living in the same environment have been per-
ceived as not responding to the environmental allergens
and not inducing an immune response. However, when
investigators have studied these non-allergic, non-atopic
individuals, the immune response to allergens, indeed,
does occur and is characterized by type 1-like lymphocyte
responses.9,10 Furthermore, T lymphocytes from normal
subjects proliferate in response to grass pollen11 and
produce increased IFN-γ10 and decreased IL-410,11 when
compared with grass pollen-sensitive subjects with aller-
gic rhinitis. The principal cytokine responsible for prolifer-
ation of Th1-type cells in response to antigen challenge
appears to be IL-12.12 Inhibition of Th2-producing T lym-
phocytes has been shown to be induced by IL-12, which
inhibits IL-4-independent B cell switching from IgG and
IgE production.13 These findings provide further support
for the concept that type-1 responses after immuno-
therapy may be driven by IL-12.
Interleukin-10 may also inhibit the pro-inflammatory
responses in the respiratory tract of non-allergic and 
non-asthmatic subjects. Increased concentrations of IL-10
are found in the airway macrophages and respiratory
epithelial cells in normal non-asthmatic individuals.14,15
Interleukin-10 is an anti-inflammatory cytokine that inhibits
cytokine release. Immunotherapy is also associated with
an increase of the anti-inflammatory cytokines IL-10 and
transforming growth factor (TGF)-β.16,17
Pollen immunotherapy is effective in selected patients.
There is questionable long-term benefit after discontinua-
tion of treatment. Immunotherapy for 3–4 years induced
prolonged clinical remission accompanied by a persistent
alteration in immunologic activity.1 This clinical improve-
ment persists for at least 3 years.
Conventional immunotherapy has been reported to
enhance production of IL-12 after grass pollen immuno-
therapy.4 Immunotherapy may be beneficial through its
capacity to increase IL-12 and decrease IL-4 production
by Th2 lymphocytes and to reduce Th2 differentiation.
Although IL-12 has been shown to be quite effective in
reversing the parameters of asthma in a mouse model, 
its intensely pro-inflammatory effects may potentially
worsen the inflammation in the respiratory tract. There-
fore, agents that increase IL-12 and IFN-γ, such as
Bacillus Calmette–Guérin (BCG) vaccine, and perhaps
DNA vaccines that also increase IL-12, such as the cyto-
sine guanosine (CpG) oligonucleotide immunostimula-
tory sequence found in many bacteria, may be a much
safer approach. Immune modulators, such as BCG and
CpG, induce the development of Th1 cells that secrete
IFN-γ and IL-12 to suppress IL-4 and IL-5 secreting Th2.
In this regard, atopy along with allergic rhinitis or asthma
symptoms could be prevented or suppressed. This immune
balance is depicted schematically in Fig. 1.
MYCOBACTERIAL VACCINES IN A MOUSE
MODEL OF ASTHMA
New approaches include the use of DNA vaccine, such
as CpG or BCG, either alone or in combination with
allergens, to stimulate antigen-presenting cells to pro-
duce cytokines that stimulate production of Th1 cells.
Bacillus Calmette–Guérin is a live, but attenuated, strain
of Mycobacterium bovis, which causes tuberculosis (TB)
disease in cows. However, there is a great deal of
research currently ongoing to develop a better vaccine
for tuberculosis. Bacillus Calmette–Guérin has been used
as the only TB vaccine for the past 80 years. It produces a
strong type-1 immune response in cell-mediated immu-
nity and is a potent stimulator of cytoxic T cells and NK
cells. It is the most effective treatment for early bladder
cancer.18 We have examined the effect of BCG and
Mycobacterium vaccae in a sensitized mouse model.19
In this model, both BCG and M. vaccae significantly
attenuated the late allergic response, the airway hyper-
reactivity to methacholine and bronchoalveolar lavage
(BAL) eosinophilia. Plasma IL-12 levels were significantly
increased and the IL-4 levels decreased following BCG or
M. vaccae in ovalbumin (OVA)-sensitized and -challenged
mice. The increase in IL-12 was greater after BCG com-
pared with M. vaccae administration. In asthma patients,
M. vaccae has been reported to partially inhibit the late
allergic response and to inhibit the dermal manifestations
of atopic eczema.20
In this allergic murine model of asthma, we have
examined many of the important features of asthma,
including airway hyperresponsiveness to methacholine,
which has long been used to characterize asthma.21
Tissue and blood eosinophilia are also hallmarks of
asthma.22,23 The late allergic reaction that occurs in
approximately 50% of patients with asthma24 was also
examined in this allergic murine model of asthma.
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Fig. 1 T helper (Th) 1/Th2 balance with delayed-type hypersensitivity being stimulated by Bacillus Calmette–Guérin vaccine with
production of interleukin (IL)-12 and interferon-γ, with allergen sensitivity stimulating IL-4 and IgE production.
Methacholine challenge performed 24 h postantigen
(OVA) challenge demonstrated airways significantly more
reactive than those in mice that were either unsensitized
or sensitized and given a BCG or M. vaccae injection.
Bacillus Calmette–Guérin-treated mice demonstrated
airway reactivity that virtually matched the results of un-
sensitized control mice (Fig. 2). Both BCG and M. vaccae
clearly attenuated the late allergic response to ovalbumin
(Fig. 3). The late allergic reaction was observed to begin
after 1 h and resolved by 6 h in sensitized control mice.
The effect of BCG and M. vaccae on BAL eosinophils was
very pronounced (Fig. 4). The positive control mice exhib-
ited 33 ± 4% eosinophils. Mice treated with BCG
showed virtually complete protection, with only 1 ± 1%
eosinophils, and M. vaccae-treated mice also showed
significant protection, with 4 ± 1% eosinophils. The un-
sensitized control mice were nearly devoid of eosinophils,
with only 1.0 ± 0.2% present. Our results on BAL
eosinophilia correlate well with the observations of Erb
et al.,25 who also found a negative correlation between
BCG and BAL eosinophilia in sensitized unchallenged
mice.
We found significantly elevated levels of IL-4 in serum
from sensitized control mice compared with the BCG-
and M. vaccae-treated mice (Fig. 5).19 Conversely, the
sensitized control mice had significantly reduced levels of
IL-12 compared with the BCG- and M. vaccae-treated
mice. The increased production of IL-12 and inhibition 
of the production of IL-4 following BCG and M. vaccae
effectively favors a type-1 cytokine profile, thus protecting
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Fig. 2 Effect of mycobacterial antigen treatment on airway
hyperresponsiveness to methacholine. Mice were challenged
24 h following ovalbumin (OVA) exposure. A dose–response
relationship to methacholine was examined. The dose of
methacholine at which a 100% increase in enhanced pause
(Penh) values was observed was designated the PC100. Non-
sensitized control mice (), sensitized control mice (), Bacillus
Calmette–Guérin-treated mice ( ) and Mycobacterium vaccae-
treated mice ( ) are shown. Data are the mean ± SEM for
seven to 12 animals in each experimental group. Differences
were significant for all groups (***P < 0.001) compared 
with sensitized controls. Reproduced with permission from
Hopfenspirger et al.19
Fig. 3 Effect of mycobacterial antigen treatment on late
allergic response (LAR) as calculated by the area under the
curve (AUC). Mice were challenged with 2% ovalbumin (OVA)
on day 24 and enhanced pause (Penh) values were recorded in
individual plethysmograph chambers for up to 9 h. The LAR
was observed to begin after 1 h and to resolve by 6 h in sen-
sitized control mice (). Arbitrary units designate values 
for each group: non-sensitized control mice (), Bacillus
Calmette–Guérin (BCG)-treated mice ( ) and Mycobacterium
vaccae-treated mice ( ). Data are the mean ± SEM for seven
to 12 animals in each experimental group. Differences were
significant for all groups (***P < 0.001, **P < 0.01) com-
pared with sensitized controls. Reproduced with permission
from Hopfenspirger et al.19
Fig. 4 Effect of mycobacterial antigen treatment on broncho-
alveolar lavage (BAL) eosinophilia. Following methacholine
challenge on day 25, percent BAL eosinophilia was deter-
mined. Non-sensitized control mice (), sensitized control mice
(), Bacillus Calmette–Guérin-treated mice ( ) and Myco-
bacterium vaccae-treated mice ( ) are shown. Data are the
mean ± SEM for seven to 12 animals in each experimental
group. Differences were significant for all groups (***P < 0.001)
compared with sensitized controls. Reproduced with permission
from Hopfenspirger et al.19
against airway hyperreactivity. Bacillus Calmette–Guérin
exhibited significantly greater levels of IL-12, even in
comparison with mice treated with M. vaccae. Most of the
other parameters reported above showed a greater effect
of BCG compared with M. vaccae, but none of these was
significantly different, except the IL-12 levels.
The timing of administration of BCG as well as the
duration of efficacy of BCG is controversial and may
explain some of the differences of the efficacy of BCG in
protection against TB as well as asthma and allergy.
We used a protocol that effectively overlapped inocu-
lation and sensitization. In a separate study, Herz et al.26
administered BCG 14 days prior to sensitization and
were successful in suppressing both allergic sensitization
and development of increased airway reactivity in mice.
However, Sano et al.27 concluded that only when both
antigen (OVA) and M. tuberculosis are presented to the
immune system in both temporal and spacial proximity
could the Th1/Th2 ratio be affected.
BACILLUS CALMETTE–GUÉRIN VACCINES IN
HUMANS
Several studies suggest a ‘window of opportunity’ period
of time during which Th cells may be made to secrete 
particular cytokines in response to a particular challenge.
Nevertheless, Marchant et al.28 have shown that in infants
the effect of BCG on Th1/Th2 populations with the
development of a Th1 response can persist for at least
1 year. Marchant et al. also showed that memory T cells
were still present 1 year following BCG administration to
newborn infants. The studies by Holt and Sly29 that pre-
vention of adult asthma by early intervention during child-
hood and the value of new immunomodulatory agents
highlight the potential value of giving BCG or other
agents at birth. Holt and Sly, as well as other investiga-
tors, support the notion it is important to prevent immune
deviation towards a Th2 response by early intervention
before environmental allergens stimulate a Th2 response
in genetically susceptible individuals.
Similarly, BCG, when given at birth or in the first
6 months of life, has been associated with a subsequent
decreased incidence of positive allergy skin tests in 
children in Guinea-Bissau, as reported by Aaby et al.30
(Fig. 6). Aaby et al.30 studied 400 children aged 3–14
years. The children underwent skin testing to house dust
mite, Dermatophagoides pteronyssinus, Dermatophagoides
farinae and cockroach. Atopy was defined as an allergy
skin test 3 mm in diameter or greater. Children receiving
BCG before the age of 6 months, and especially in the
first 7–31 days, had a significantly lower odds ratio (OR)
of developing atopy. For example, the OR of children
receiving BCG in the first week of life was 0.1 of having a
positive allergy skin test. Those receiving BCG after the
age of 6 months had an OR of approximately 0.5–0.6.
Similarly, the percentage of children having a positive
skin test was approximately 3% for children receiving
BCG in the first week of life, in contrast with approxi-
mately 15% atopic, as defined by having a positive allergy
skin test, for children receiving BCG after 6 months.
Retrospective studies of BCG have been contro-
versial. Thus, the studies performed in Japan31 and in
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Fig. 5 Effect of mycobacterial antigen treatment on serum
interleukin (IL)-4 and IL-12 concentrations. Serum collected
from mice on day 25 was measured by ELISA for content of the
cytokines IL-4 (a) and IL-12 (b). Shown are sensitized control
mice (), Bacillus Calmette–Guérin (BCG)-treated mice ( )
and Mycobacterium vaccae-treated mice ( ). Values for either
cytokine were undetectable in non-sensitized control mice.
Data are the mean ± SEM for seven to 12 animals in each
experimental group. Differences were significant for all groups
(***P < 0.001, **P < 0.01) compared with sensitized controls.
In the case of IL-12 concentration, differences between the
BCG- and M. vaccae-treated groups were also significant.
Reproduced with permission from Hopfenspirger et al.19
Guinea-Bassau30 showed an inverse correlation between
mycobacteria exposure and markers of atopy/asthma. In
contrast, the Scandinavian studies32,33 failed to show any
protective effect of mycobacteria towards markers of
atopy/asthma. These differences may be explained by
genetic background, the dose and strain of BCG used,
the type of mycobacteria exposure and the traits of
indigenous mycobacteria, as well as the age at time of
exposure and other confounding factors.
Alm et al.,32 in Scandinavia, have challenged the con-
clusions of Shirikawa et al.31 in Japan. Alm et al. found
early BCG vaccination in children with atopic risk factors
did not alter the children’s chances of developing atopy
themselves. The retrospective study of Alm et al. differs
from the study of Shirakawa et al. in that the subjects in
the former study received BCG up until 6 months of age,
whereas those in the study of Shirikawa et al. received
BCG at birth or only up until 2 months of age (Fig. 7).
Furthermore, the incidence of tuberculosis was signifi-
cantly higher in Japan at the time the studies of Shirikawa
et al. were performed compared with the incidence of
tuberculosis in Sweden. Other studies showing conflicting
results were those of Omenass et al.,33 who also reported
the absence of a relationship between tuberculin reactiv-
ity and atopy in BCG-vaccinated young adults. Thus, the
timing of BCG delivery may be very important and
demonstrates the importance of a memory type-1
cytokine response in newborns.
For this reason, our group has undertaken a prospec-
tive study in three countries. We studied the effect of BCG
on the development of atopy and asthma. This study is
currently being conducted in Istanbul, Turkey, Cordoba,
Argentina, and Bangkok, Thailand. Children were ran-
domly enrolled from clinics at birth and received the 
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Fig. 7 The inverse association between tuberculin responses
and atopic disorder. The ordinate is the percentage of 860 
12-year-old children who received Bacillus Calmette–Guérin
(BCG) at birth and developed atopy or atopic disease. ( ),
children who were tuberculin negative; (), children who were
tuberculin positive at age 6 years but were negative at age 12;
(), children who became tuberculin positive at age 12; ( ),
children who were tuberculin positive at both 6 and 12 years 
of age. *P < 0.01 compared with tuberculin-negative children.
Adapted from Shirakawa et al.31
Fig. 6 Early Bacillus Calmette–Guérin (BCG) vaccination and reduction in atopy in Guinea-Bissau.30 Four hundred 
children aged between 3 and 14 years were skin tested to house dust mite Dermatophagoides pteronyssinus, Dermatophagoides
farinae and cockroach. A positive skin test was > 3 mm and is recorded on the left ordinate as percentage and the odds ratio (OR)
of developing atopy is recorded on the right ordinate. The abscissa is the time of receiving BCG. Adapted from Aaby et al.30
BCG supplied by their local public health department.
They were followed by their private or university physi-
cian. A questionnaire concerning family occurrences of
allergic diseases was administered at enrollment. A puri-
fied protein derivative (PPD) was administered between 
9 and 12 months of age and the size of the reaction was
measured. The BCG scar was noted. The families were
recontacted when children were 2 years of age for an
allergy skin test panel, International Standardized Asthma
in Allergy Children (ISAAC) questionnaire and a PPD if
not done previously. There were a total of 1700 children
enrolled in the study: 550 from Thailand and Argentina
and 600 from Istanbul (Fig. 8).
Argentina had a significantly higher total of parents
with asthma or allergic rhinitis than each of the other
countries. Fifty-three mothers had asthma, 89 mothers
had hay fever, 53 fathers had asthma and 83 fathers had
hay fever. In contrast, those enrolled from Turkey and
Thailand had approximately the same number of parents
with asthma or allergic rhinitis. Their totals were approxi-
mately one-half to one-third the number seen in Argentina
(Table 1).
A history of smoking during pregnancy was noted in 68
mothers in Turkey and in 62 mothers in Argentina and
Turkey, but in only 17 mothers in Thailand. House pets,
however, were noted in 178 homes in Thailand, whereas
there were only 53 household with pets in Turkey. These
differences were significant from the other site in terms of
home pets and smoking during pregnancy.
In Thailand, there was no difference with a PPD posi-
tive or negative skin test for the presence of allergy skin
test. However, there was a significantly lower incidence
(P = 0.01) of ISAAC allergic histories in PPD-positive
children. Similarly, in Istanbul, there was no difference
between children with a PPD positive or negative for the
presence of a positive allergy skin test. However, there
was a significantly lower incidence (P = 0.004) of ISAAC
allergic histories in PPD-positive children. In Argentina,
there was no significant difference in children with a PPD
positive or negative for the presence of a positive allergy
skin test. However, in all three countries, there was a trend
towards a lower incidence of positive allergy skin test in
individuals who were PPD positive.
We tested the hypothesis that BCG can promote a Th1
immune response and decrease Th2 activity. Published
retrospectives on BCG and atopy/allergy have been con-
flicting. We report the 2 year data of a 5 year prospective
study of the effect of BCG on asthma, allergy, and atopy
(RG Townley et al., unpubl. obs., 2001). Seventeen hundred
newborns were enrolled without regard to family history
of allergy and approximately 650 have been evaluated at
the age of 2 years. Argentina had an incidence of ISAAC
allergic histories of 40% compared with 20–30% in the
other two countries. In Thailand and Istanbul, there was a
lower incidence of ISAAC allergic history in those children
with a positive PPD response. The allergy skin test data
may suggest the non-discriminatory nature of allergy skin
tests in 2-year-old children and suggest our data at 5 years
may be more valuable.
DNA VACCINES USING CPG
Recombinant technology now offers the possibility of
entirely new approaches to allergen immunotherapy.
Many of the major inhalant allergens have been identi-
fied, cloned and sequenced and expressed in a variety of
systems.34
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Fig. 8 Enrollment at birth of newborns from the three inter-
national sites. The ordinate is the number of newborns receiv-
ing Bacillus Calmette–Guérin. ( ), total number enrolled; (),
the number who were tuberculin skin tested at age 9 months;
(), the number of children who had allergen skin tests at age
2 years.
Table 1 Demographic, familial and environmental charac-
teristics of enrolled subjects
Thailand Turkey Argentina
No. enrolled 550 604 550
Mother with asthma (n) 15 11 53*
Mother with hay fever (n) 44 30 89*
Father with asthma (n) 18 16 53*
Father with hay fever (n) 40 19 83*
Both parents with Asthma (n) 0 1 3
Mother smoked in pregnancy (n) 17 68 62
Indoor smoker (n) 138 153 228*
Home pet (n) 178 53† 338
*Argentina significantly higher than the other two countries.
†Turkey significantly lower than the other two countries.
Incorporation of the allergen protein cDNA into a
plasmid and then injected intradermally results in persis-
tence of the plasmid DNA without replication or incor-
poration into the host genome.35,36 This plasmid DNA
incorporating an allergen protein into the plasmid
resulted in no inflammatory reaction at the site of injec-
tion and production of the encoded protein, which is then
released from the surface of the cell and integrated into
peptide fragments that are presented to the cells major
histocompatibility complex (MHC) class 1 molecules.36
These studies in rats showed the cDNA for dust mite
antigen Der p5 was incorporated into the plasmid vector.
Expression of the Der p5 could be demonstrated with the
antibody response to Der p5, which peaked at 4 weeks
and virtually returned to baseline at 6 weeks. These rats
demonstrated marked inhibition of the IgE response to
Der p5 and decreased airway and basophil sensitivity 
to Der p5. This study supported the concept that the 
peptides derived from the encoded protein would be pre-
sented by MHC class 1 antigens to CD8+ T lymphocytes,
favoring a cell-mediated Th1 response to the protein.
DNA vaccines act by producing antigens in the host.
Antigen processing is through MHC classes I and II. In
animal studies, immunity is long lasting, broad based and
results in antibodies, as well as cell-mediated immunity.
DNA vaccines are possible targets for influenza, human
immunodeficiency virus, Herpes simplex, human papillo-
mavirus, hepatitis B and C and TB. Other targets include
a variety of parasitic diseases, including malaria, schisto-
somiasis, leishmaniasis, rotavirus, and bacterial toxins.37
The advantages of intramuscular DNA compared with
live virus vaccines are that the DNA vaccines are pro-
duced by fermentation, purified chemically, result in a
single chemical entity, flexibility to engineer the antigen is
markedly enhanced and the technology is one that can
result in generic delivery. Early trials with oligonucleotide
DNA vaccine using CpG showed they were safe and effi-
cacious in preventing hepatitis B when conjugated with
hepatitis B.37 Gene vaccination using plasma DNA results
in induced Th1 response that dominated the Th2 response,
whereas anaphylaxis is a risk in classic immunotherapy.
This appears to be overcome by plasma DNA encoding
the allergen because very low doses of antigen are used
in contrast with conventional immunotherapy. In mice,
protein immunization induced a Th2 response.37 In con-
trast, plasma DNA induced Th1 responses with IgG2A
antibody production and IFN-γ.
In studies published by Spiegelberg et al.,38 it was
demonstrated that boosting of mice primed with antigen
resulted in a 75% decrease of the IgE titer using plasma
DNA encoding the antigen. Furthermore, this plasmid
DNA using CpG immunization inhibited lung eosino-
philia through a mechanism that elicited a Th1 response
with induction of IL-12 and IFN-α and IFN-β. It also
induced a Th1 immune response to the allergen and
appears to be a novel type of immunotherapy.
The advantages of plasma DNA compared with 
classical immunotherapy are only very small amounts of
allergen are secreted and the allergen gene can be 
modified. Furthermore, DNA vaccines are likely to have 
a long-lasting effect and allow the elimination of the
active site of the enzyme contained in allergens used in
classic immunotherapy. Constructs can be made to
contain the optimal number and location of the immuno-
stimulatory sequence. The CpG motifs may oppose 
Th2-type allergic responses and coadministration of CpG
oligonucleotide with antigen or allergen may protect
against asthma.
Additional studies by Klein et al.39 also showed the
effectiveness of CpG oligonucleotide in a mouse model
of asthma. In their studies, Klein et al.39 mixed the aller-
gen with the CpG, in contrast with the study of
Spiegelberg et al.,38 who covalently linked the allergen
with the CpG. Klein et al.39 also showed inhibition of the
serum IgE and inhibition of pulmonary eosinophilia, as
well as airway reactivity, in mice receiving CpG along
with the antigen compared with control mice that
received the same antigen but without the CpG.
These studies raise the possibility that childhood expo-
sure of CpG DNA may restore a Th1 immune response
and may improve the beneficial effects of immuno-
therapy, partly due to induction of Th1 cytokines. Currently,
studies are in progress to determine the effectiveness in
ragweed seasonal allergic rhinitis patients of administer-
ing CpG with ragweed allergen.
The promise of major improvements in the practice of
allergen immunotherapy by stimulating the innate
immune system favorable to a Th1 response to allergens
offers a promising alternative to conventional immuno-
therapy. Studies in experimental animals appear to be
very promising, including those involving either BCG
vaccine or DNA vaccine incorporating immunostimulatory
sequence oligonucleotides. However, these studies per-
formed in experimental animals and in vitro could prove to
be disappointing in clinical trials. In this regard, it is not
possible to predict whether stimulation of the immune
system towards a non-allergic response to allergens will
prove to be more effective for future immunotherapy.
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INHIBITORS OF IL-4 AND IL-5 GIVEN BY
INHALATION ONCE A WEEK
Soluble recombinant IL-4 receptor (IL-4R) is currently
under investigation and has been shown in preliminary
studies (Immunex, Seattle, WA, USA, unpubl. obs.) to be
safe and effective in asthmatics. Interleukin-4R combines
with IL-4 to block its effect and improve pulmonary func-
tion and asthma symptom scores. Early indications are
that IL-4 can decrease asthma exacerbation and decrease
β-adrenergic receptor agonist rescue use, inhaled steroid
use, exhaled nitric oxide (NO) and circulating eosino-
phils. However, a recent phase III trial has been some-
what disappointing (Immunex, Seattle, WA, USA,
unpubl. obs.).
A recombinant humanized monoclonal antibody
against IL-5 has been evaluated in patients with mild
asthma. It markedly decreased blood eosinophils and
reduced the number of sputum eosinophils. However, it
had no apparent effect on allergen-induced late-phase
reaction or airway hyperresponsiveness. It remains to be
seen whether longer-term administration of anti-IL-5 to
eliminate tissue eosinophils in the airways is associated
with improvement in asthma symptoms and airway hyper-
responsiveness.
ANTIBODY AGAINST IGE: OMALIZUMAB
Also under evaluation is a strategy to block IgE and its
synthesis. A recombinant humanized monoclonal anti-
body against IgE called rhuMAb-E25, or omalizumab,
markedly decreases serum IgE and IgE receptor expres-
sion on basophils and inhibited IgE production by B
cells.40 This antibody is specific for the epitope of IgE that
binds to the IgE receptor, thereby blocking the binding of
IgE to mast cells and inhibiting mediator release. In con-
trolled phase II and phase III trials in patients with moder-
ate to severe asthma, omalizumab significantly improved
symptoms, peak flow rates and decreased rescue use of
β-adrenergic receptor agonists, inhaled or oral cortico-
steroid use,40 exhaled NO,41 blood and sputum eosino-
phils and the early and late allergic response.41
We evaluated the effects of the anti-IgE antibody oma-
lizumab on exhaled NO in 29 children with allergic
asthma.42 Exhaled NO was assessed during the stable
dose of therapy with inhaled beclomethasone for 6
weeks, during the beclomethasone reduction and with-
drawal phase of 12 weeks and also during an open
extension phase (24 weeks). During the steroid-reduction
phase, exhaled NO remained stable in the omalizumab-
treated group and rose non-significantly in the placebo
group. Significant differences in exhaled NO between
groups occurred towards the end of steroid withdrawal.
At the end of the open-label extension of omalizumab in
the omalizumab-treated group, exhaled NO decreased
significantly from baseline, even though beclomethasone
was markedly reduced. When placebo patients switched
to omalizumab for the open extension, exhaled NO fell
significantly, although the doses of beclomethasone
remained very low. Our studies suggest omalizumab sup-
pressed airway inflammation during beclomethasone
withdrawal. These results demonstrate that omalizumab,
like corticosteroids and leukotriene-modifying agents,
suppresses exhaled NO. Treatment with anti-IgE antibody
reduces both the early and late airway responses to aller-
gen challenge and also leads to significant improvement
in asthma control in patients with moderate to severe
chronic asthma. However, these findings do not prove
that IgE entirely mediates the response to allergen.
Further studies are needed to examine the dose or time
dependency of anti-IgE effects. It is possible that very low
levels of IgE persist in the airway mast cells for long
periods after serum IgE has been reduced to very low or
undetectable levels. The ability of omalizumab to main-
tain long-term control in patients with moderate to severe
asthma followed for 52 weeks total was reported in a
large multinational study.40 In the extension phase of
24 weeks, more omalizumab-treated patients (33.5%)
than the placebo-treated patients (13.5%) were able to
complete the extension phase without requiring inhaled
corticosteroid treatment (P < 0.001).
It is entirely feasible that combining anti-IgE with con-
ventional immunotherapy may provide a more effective,
safer and longer-term efficacy than either modality alone.
For example, anti-IgE may, by virtue of markedly decreas-
ing the level of IgE in the serum and on mast cells,
decrease the severity and incidence of anaphylactic 
reactions associated with conventional immunotherapy.
Conventional immunotherapy, either alone or combined
with immunostimulatory sequences of CpG or BCG, may
enhance their effectiveness and duration of action through
a mechanism mediated by increasing Th1 and decreas-
ing Th2 responses. These immune responses may be
further enhanced when combined with anti-IgE. Only
future clinical trials will determine whether these concepts
prove correct.
We now have many modalities of immunomodulation
to decrease the effect of IL-4 or IL-5 or production and
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levels of IgE or agents to shift the immune response from
a Th2 to Th1 and thereby decrease the allergic inflam-
matory response in the airways.
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